Logo Logo
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Springe zu: 2022 | 2019 | 2016 | 2015
Anzahl der Publikationen: 20

2022

Wuerstlein, R.; Ellis, P.; Montemurro, F.; Anton Torres, A.; Delaloge, S.; Zhang, Q.; Wang, X.; Wang, S.; Shao, Z.; Li, H.; Rachman, A.; Vongsaisuwon, M.; Liu, H.; Fear, S.; Pena-Murillo, C. und Barrios, C. (2022): Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer. In: Esmo Open, Bd. 7, Nr. 5 [PDF, 484kB]

2019

Wuerstlein, R.; Kates, R.; Gluz, O.; Grischke, E. M.; Schem, C.; Thill, M.; Hasmüller, S.; Köhler, A.; Otremba, B.; Griesinger, F.; Schindlbeck, C.; Trojan, A.; Otto, F.; Knauer, M.; Pusch, R. und Harbeck, N. (2019): Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study. In: Breast Cancer Research and Treatment, Bd. 175, Nr. 2: S. 389-399

2016

Burgmann, M.; Hermelink, K.; Farr, A.; Meegen, F. van; Engel, J.; Harbeck, N. und Wuerstlein, R. (2016): Young breast cancer survivors-reproductive concerns, life satisfaction and cancer-specific distress. In: Oncology Research and Treatment, Bd. 39: S. 48

Wuerstlein, R.; Prat, A.; Ortega, V; Pare, L.; Galvan, P.; Nuciforo, P.; Oliverira, M.; Amillano, K.; Lopez, R.; Lluch, A.; Morales, S.; Gonzales, R.; Manso, L.; Martinez, J.; Llombart, A.; Pena, L. de la; Di Cosimo, S.; Rubio, I; Baselga, J.; Cortes, J. und Harbeck, N. (2016): Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer. In: Oncology Research and Treatment, Bd. 39: S. 182-183

Kolben, Thomas; Augustine, D.; Armbrust, R.; Kolben, T. M.; Degenhardt, T.; Burgmann, M.; Goess, C.; Ditsch, N.; Kates, R.; Harbeck, N. und Wuerstlein, R. (2016): Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer. In: Breast Cancer Research and Treatment, Bd. 155, Nr. 1: S. 109-115

Gluz, O.; Nitz, U.; Christgen, M.; Kates, R.; Clemens, M.; Kraemer, S.; Nuding, B.; Aktas, B.; Kuemmel, S.; Reimer, T.; Lorenz-Salehi, F.; Krabisch, P.; Just, M.; Augustin, D.; Liedtke, C.; Svedman, C.; Shak, S.; Wuerstlein, R.; Kreipe, H. und Harbeck, N. (2016): Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer. In: European Journal of Cancer, Bd. 57: S6-S6

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Ghali, N.; Orujov, E.; Kates, R. E.; Cowens, W.; Hornberger, J.; Pelz, E. und Harbeck, N. (2016): The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. In: Current Medical Research and Opinion, Bd. 32, Nr. 7: S. 1217-1224

Schindler, F.; Schinkoethe, T.; Kirkovits, T.; Drewes, C.; Harbeck, N. und Wuerstlein, R. (2016): eHealth acceptance in breast cancer care. In: Oncology Research and Treatment, Bd. 39: S. 52-53

Wuerstlein, R.; Burgmann, M.; Lotz, A.; Schlager, V.; Engel, J.; Harbeck, N. und Hermelink, K. (2016): Life satisfaction and life quality in the elderly patient with breast cancer. In: Oncology Research and Treatment, Bd. 39: S. 51

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Hofmann, D.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Morel, P.; Cowens, W.; Hornberger, A.; Kates, R. E.; Pelz, E. und Harbeck, N. (2016): Prosigna® results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study. In: Oncology Research and Treatment, Bd. 39: S. 49

Braun, M.; Gluz, O.; Nitz, U.; Christgen, M.; Kuemmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Kates, R. E.; Wuerstlein, R.; Kreipe, H.-H. und Harbecks, N. (2016): Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer. In: Oncology Research and Treatment, Bd. 39: S. 2

Untch, M.; Augustin, D.; Ettl, J.; Haidinger, R.; Harbeck, N.; Lück, H.-J.; Lüftner, D.; Marée, F.; Müller, L.; Overkamp, F.; Ruckhäberle, E.; Thill, M.; Thomssen, C.; Wuerstlein, R. und Marschner, N. (2016): ABC3 Consensus Commented from the Perspective of the German Guidelines Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07.11.2015. In: Geburtshilfe und Frauenheilkunde, Bd. 76, Nr. 2: S. 156-163

Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Sotlar, K.; Grischke, E. M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; Pelz, E.; Kates, R. E.; Wuerstlein, R.; Kreipe, H. H. und Harbeck, N. (2016): Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. In: Cancer Research, Bd. 76

Harbeck, N.; Gluz, O.; Christgen, M.; Braun, M.; Kuemmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Kates, R. E.; Wuerstlein, R.; Haas, S. L. de; Kiermaier, A.; Kreipe, H. H. und Nitz, U. (2016): Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer. In: Cancer Research, Bd. 76

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Hofmann, D.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Morel, P.; Cowens, W.; Hornberger, J.; Kates, R. E.; Pelz, E. und Harbeck, N. (2016): Prosigna®(R) results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study. In: Cancer Research, Bd. 76

Burgmann, M.; Hermelink, K.; Farr, A.; Heiduschka, A.; Meegen, F. van; Engel, J.; Harbeck, N. und Wuerstlein, R. (2016): Cancer-specific distress, life satisfaction and parenting concerns in young breast cancer survivors. In: Cancer Research, Bd. 76

Kolben, T.; Schwarz, T. M.; Goess, C.; Blume, C.; Degenhardt, T.; Engel, J.; Wuerstlein, R.; Ditsch, N.; Harbeck, N. und Kahlert, S. (2016): Surcigal management of ipsilateral breast tumor recurrence. In: Cancer Research, Bd. 76

Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Sotlar, K.; Grischke, E. M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; Pelz, E.; Kates, R. E.; Wuerstlein, R.; Kreipe, H. H. und Harbeck, N. (2016): Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. In: Cancer Research, Bd. 76

2015

Kolben, T.; Harbeck, N.; Wuerstlein, R.; Schubert-Fritschle, Gabriele; Bauerfeind, I.; Schrodi, Simone und Engel, Jutta (2015): Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry. In: Breast, Bd. 24, Nr. 1: S. 24-31

Kolben, T.; Schwarz, T. M.; Goess, C.; Blume, C.; Degenhardt, T.; Engel, Jutta; Wuerstlein, R.; Ditsch, N.; Harbeck, N. und Kahlert, S. (2015): Surgical management of ipsilateral breast tumor recurrence. In: International Journal of Surgery, Bd. 23, Nr. Pt A: S. 141-146

Diese Liste wurde am Sat Dec 21 22:29:43 2024 CET erstellt.